Metabolic Reprogramming to Improve Immunotherapy (R21)

The overall goal of this funding opportunity announcement (FOA) is to encourage R21 exploratory/developmental grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.